Just wondering whether it may have something to do with this?
https://hotcrapper.com.au/documentdownload?id=uOMxKKzFkiWRTLKhOROKAxjvSDYL4Au8zBD/v/V38LFiGug=
Page 37
Legacy Oncology Asset Monetization to Drive Value: BNC101
• Exclusive Agreement to license Bionomics’ BNC101 oncology
drug candidate to Carina Biotech for the development of
Chimeric Antigen Receptor T cell (CAR-T) therapy, which
harnesses the body’s immune system to fight cancer.
• Bionomics is eligible to receive up to A$118 million in clinical &
development milestones plus royalty payments if Carina fully
develops and markets the new therapy. In the event that
Carina sub-licenses the CAR-T treatment, Bionomics is eligible
to share in the sub-licensing revenues in early clinical
development and receive a substantial double-digit portion of
the revenues in later stages of clinical development.
• In September 2021, Carina announced that it plans to initiate a
clinical trial of BNC101 CAR-T therapy for the treatment of
advanced colorectal (bowel) cancer in late 2022
•
Bionomics retains BNC101 for other types of therapies
https://www.frontiersin.org/articles/10.3389/fcimb.2020.00410/full
Engineering CAR T Cells to Target the HIV Reservoir
Wenli Mu†,
Mayra A. Carrillo† and
Scott G. Kitchen*†
- Division of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, United States
The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that reactivating the latent reservoir will allow subsequent elimination by the host anti-HIV immune cells. However, clinical trials testing certain classes of latency reactivating agents (LRAs) have so far revealed the minimal impact on reducing the viral reservoir. A robust immune response to reactivated HIV expressing cells is critical for this strategy to work. A current focus to enhance anti-HIV immunity is through the use of chimeric antigen receptors (CARs). Currently, HIV-specific CARs are being applied to peripheral T cells, NK cells, and stem cells to boost recognition and killing of HIV infected cells. In this review, we summarize current developments in engineering HIV directed CAR-expressing cells to facilitate HIV elimination. We also summarize current LRAs that enhance the “kick” strategy and how new generation and combinations of LRAs with HIV specific CAR T cell therapies could provide an optimal strategy to target the viral reservoir and achieve HIV clearance from the body.
BNO.pdf
https://hotcrapper.com.au/styles/HC/images/icon-pdf.png
